Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.32 |
| ▸ | ASPH | Q12797 | 1/20 | 0.32 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11724604 | 0.79 | L3MBTL1 (0.43) | HTTALDH1A1L3MBTL1MAPTGAA | |
| SCHEMBL3942505 | 0.79 | L3MBTL1 (0.36) | SMN1; SMN2CYP1A2HTTALDH1A1L3MBTL1 | |
| SCHEMBL8074924 | 0.77 | HSD17B10 (0.47) | SMN1; SMN2HTTALDH1A1L3MBTL1KDM4E | |
| SCHEMBL23959818 | 0.76 | RAB9A (0.36) | ALDH1A1KDM4ERAB9A | |
| SCHEMBL13990922 | 0.76 | EPHX2 (0.41) | ALDH1A1L3MBTL1GAARAB9A | |
| SCHEMBL4077561 | 0.74 | ATM (0.48) | SMN1; SMN2ALDH1A1L3MBTL1GAARAB9A | |
| SCHEMBL14067222 | 0.74 | — | — | |
| SCHEMBL1237249 | 0.73 | — | — | |
| SCHEMBL7433083 | 0.71 | GAA (0.45) | SMN1; SMN2MAPK1ALDH1A1L3MBTL1GAA | |
| SCHEMBL7747841 | 0.70 | ALDH1A1 (0.39) | SMN1; SMN2HTTALDH1A1L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 499 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2722051-A1 | Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus | Seattle Genetics, Inc. (US) | 2014-04-23 | — | — | EP | claimed |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | SEATTLE GENETICS, INC. (US) | 2009-01-15 | — | — | US | claimed |
| EP-1917020-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | Seattle Genetics, Inc. (US) | 2008-05-07 | — | — | EP | claimed |
| EP-1761554-A2 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | Biosource Pharm, Inc. (US) | 2007-03-14 | — | — | EP | claimed |
| WO-2007008603-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| US-20060281687-A1 | Cyclin groove inhibitors | CYCLACEL LIMITED (GB) | 2006-12-14 | — | — | US | claimed |
| WO-2006083317-A2 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | BIOSOURCE PHARM, INC. (US) | 2006-08-10 | — | — | WO | claimed |
| EP-1675868-A2 | CYCLIN GROOVE INHIBITORS | Cyclacel Limited (GB) | 2006-07-05 | — | — | EP | claimed |
| US-7015306-B2 | Labeled neurotensin derivatives | BIOSYNTHEMA, INC. (US) | 2006-03-21 | — | — | US | claimed |
| US-20050191240-A1 | Peptide analogs of neurotensin resistant to enzymatic degradation and retain high binding affinity for neurotensin receptors; metal chelating group on one end; replacing Arg8 with Gly(PipAm) ((N-amidinopiperidinyl)glycine) for example; useful for diagnostic and therapeutic purposes | ADVANCED ACCELERATOR APPLICATIONS USA, INC. | 2005-09-01 | — | — | US | claimed |
| WO-2005042565-A2 | CYCLIN GROOVE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-05-12 | — | — | WO | claimed |
| EP-1194444-A2 | LABELED NEUROTENSIN DERIVATIVES WITH IMPROVED RESISTANCE TO ENZYMATIC DEGRADATION | BioSynthema Inc. (US) | 2002-04-10 | — | — | EP | claimed |
| WO-2000078796-A2 | LABELED NEUROTENSIN DERIVATIVES WITH IMPROVED RESISTANCE TO ENZYMATIC DEGRADATION | MALLINCKRODT INC. (US) | 2000-12-28 | — | — | WO | claimed |
| US-20260055150-A1 | GRAIL-1 PEPTIDE PRODUCTS AND METHODS | UNIV MICHIGAN (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4680108-A1 | PEPTIDE MULTIMER PRODUCTS AND METHODS | The Regents of The University of Michigan (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250263439-A1 | HETERODIMERIC PEPTIDE REAGENTS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-08-21 | — | — | US | disclosed |
| EP-0772628-A1 | PEPTIDE DERIVED RADIONUCLIDE CHELATORS | RESOLUTION PHARMACEUTICALS INC. (CA) | 1997-05-14 | — | — | EP | disclosed |
| EP-0731789-A1 | DP-IV-SERINE PROTEASE INHIBITORS | FERRING B.V. (NL) | 1996-09-18 | — | — | EP | disclosed |
| WO-1996003427-A1 | PEPTIDE DERIVED RADIONUCLIDE CHELATORS | RESOLUTION PHARMACEUTICALS INC. (CA) | 1996-02-08 | — | — | WO | disclosed |
| WO-1995015309-A1 | DP-IV-SERINE PROTEASE INHIBITORS | FERRING B.V. (NL) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055150-A1 | GRAIL-1 PEPTIDE PRODUCTS AND METHODS | TP53, TP53BP1, DDIT3 | SMN1; SMN2 4067/4885CYP1A2 4787/4885MAPK1 475/4885 |
| US-20250263439-A1 | HETERODIMERIC PEPTIDE REAGENTS AND METHODS | ERBB2, EGFR, ERBB3 | SMN1; SMN2 3404/4885CYP1A2 4730/4885MAPK1 1636/4885 |
| US-20060281687-A1 | Cyclin groove inhibitors | CCNC, CCNH, CCNI | SMN1; SMN2 3901/4885CYP1A2 4091/4885MAPK1 1347/4885 |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | MMAB, DNPEP, MARCKS | SMN1; SMN2 4221/4885CYP1A2 4197/4885MAPK1 2998/4885 |
| US-20050191240-A1 | Peptide analogs of neurotensin resistant to enzymatic degradation and retain high binding affinity for neurotensin receptors; metal chelating group on one end; replacing Arg8 with Gly(PipAm) ((N-amidinopiperidinyl)glycine) for example; useful for diagnostic and therapeutic purposes | ANPEP, DNPEP, NTSR1 | SMN1; SMN2 1507/4885CYP1A2 4796/4885MAPK1 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.